Rythmol SR and Sotalol Injection
Determining the interaction of Rythmol SR and Sotalol Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using propafenone together with sotalol can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration of propafenone with Class IA antiarrhythmic agents may produce additive effects on the QT interval of the electrocardiogram. Theoretically, this may increase the risk of ventricular arrhythmias including torsade de pointes and sudden death. Conflicting information exists as to whether propafenone alone prolongs the QT interval. Some clinicians suggest it does, although data in the medical literature do not support a clinically significant effect of propafenone and other Class IC agents on the QT interval. Moreover, because propafenone prolongs the QRS interval in the electrocardiogram, any changes in the QT interval are difficult to interpret. Nevertheless, proarrhythmic effects including sudden death and life-threatening ventricular arrhythmias such as ventricular fibrillation, ventricular tachycardia, asystole, and torsade de pointes have been associated with its use. Since propafenone has not been extensively studied for use in conjunction with other antiarrhythmic agents or agents that prolong the QT interval, caution may be advisable. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).
MANAGEMENT: Propafenone product labeling recommends that concomitant use with Class IA and III antiarrhythmic agents be avoided. In addition, these agents should be withheld for at least 5 half-lives prior to dosing with propafenone. Close monitoring of clinical response, ECG, and drug levels is recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
- Klein RC, Huang SK, Marcus FI, et al "Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine." Am Heart J 114 (1987): 551-8
- Hii JT, Wyse DG, Gillis AM, et al "Propafenone-induced torsade de pointes: cross-reactivity with quinidine." Pacing Clin Electrophysiol 14 (1991): 1568-70
- "Product Information. Rythmol SR (propafenone)." GlaxoSmithKline, Research Triangle Park, NC.
- Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8
- "Product Information. Rhythmol (propafenone)." Knoll Pharmaceutical Company, Whippany, NJ.
- Zehender M, Hohnloser S, Geibel A, et al "Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients." Br Heart J 67 (1992): 491-7
Generic Name: propafenone
Brand name: Rythmol, Rythmol SR
Synonyms: Rythmol Extended Release
Generic Name: sotalol
Brand name: Betapace, Betapace AF, Sorine, Sotalol Hydrochloride AF, Sotylize
Synonyms: Sotalol
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.